COMMUNIQUÉS West-GlobeNewswire

Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
31/07/2025
JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision [...]
Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production
31/07/2025
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified [...]
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
31/07/2025
New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) ‘time saved’ by early-start ADAS-Cog13 difference: −5.43 (P = 0.0035), ADCS-ADL difference: +9.50 (P < 0.0001) Restoring [...]
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
31/07/2025
CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems Company will expand testing services and broaden regional [...]
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
31/07/2025
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present [...]
Kura Oncology to Report Second Quarter 2025 Financial Results
31/07/2025
SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
31/07/2025
PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company [...]
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
31/07/2025
Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors Recent Leadership Appointments Bring Deep Experience in [...]
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
31/07/2025
Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases; thrombocytopenia [...]
VedTechBio Unveils Next-Gen Drug Discovery AI; Partners with AlphaMeld in Multi-Therapy Collaboration
31/07/2025
BENGALURU, India, July 31, 2025 (GLOBE NEWSWIRE) -- VedTechBio Research Pvt. Ltd., a pioneer in AI-driven drug discovery, today announced major enhancements to its RxAgentAI™ platform, cutting drug discovery timelines [...]
Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
31/07/2025
Reduce development timelines and costs, while improving access to life-saving treatments VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Onco-Innovations Limited (CBOE CA: ONCO ) (OTCQB: ONNVF ) ( [...]
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
31/07/2025
BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of [...]
Nautilus Biotechnology Reports Second Quarter 2025 Financial Results
31/07/2025
SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second [...]
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7
31/07/2025
DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a [...]
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
31/07/2025
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will [...]
Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award
31/07/2025
GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Michelle LeRoux Williams, Chief [...]
PL BioScience Announces Major Site Expansion
31/07/2025
New 1,200 m² facility in Aachen expands headquarters to support company growth and scale Human Platelet Lysate production Site provides the world’s largest HPL output with 20,000L annual capacity and a dual-source GMP [...]
VedTechBio Unveils Next-Gen Drug Discovery AI; Partners with AlphaMeld in Multi-Therapy Collaboration
31/07/2025
BENGALURU, India, July 31, 2025 (GLOBE NEWSWIRE) -- VedTechBio Research Pvt. Ltd., a pioneer in AI-driven drug discovery, today announced major enhancements to its RxAgentAI™ platform cutting drug discovery timelines in [...]
Ipsen publie de solides résultats au premier semestre 2025 et relève ses objectifs financiers annuels
31/07/2025
Croissance des ventes totales du Groupe de 11,4% à taux de change constant 1 ou 9,7% en données publiées, tirée par les trois aires thérapeutiques : 95,7% dans les Maladies Rares, 9,7% en Neurosciences et 6,4% en [...]

Pages